The next‑generation, AI‑designed pan‑EGFR inhibitor for EGFR‑mutant lung cancer significantly expands the Company’s oncology pipeline Targeting a $16.2 Billion Market Opportunity
Transformative clinical pipeline transaction will add CL-273, a pan-EGFR inhibitor, and CL-741, a Phase 1-Ready c-MET inhibitor, to Kairos Pharma's clinical portfolio to target multi-billion dollar lung...
CSO Neil Bhowmick to deliver company presentation and will be available for investor meetings
Company recognized for advancing ENV‑105, a first‑in‑class resistance‑modulating antibody for metastatic castration‑resistant prostate cancer
Company makes important progress in 2025 and looks ahead into 2026
Interim efficacy analysis highlights potential value of combination therapy of ENV-105 and apalutamide following positive safety data
Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Kairos Pharma,...
Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Kairos Pharma,...
Kairos Pharma, Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company dedicated to addressing resistance to current cancer therapeutics, today announced that it has been selected to present...
Interim efficacy analysis highlights potential value of combination therapy of apalutamide and ENV105 following positive safety data Company to host virtual KOL discussion...